Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sciele Pharma said that the FDA has accepted the supplemental new drug application for Sciele's new Sular formulation.
Subscribe to our email newsletter
Sular is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.
The companies said that they expect to hear more from the FDA on November 2.